Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.

Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.

Abstract: The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.

Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. Inanother aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.

Abstract: Oligonucleotides capable of modifying or inhibiting in vivo or in vitro expression of a target gene wherein the oligonucleotide has an antisense sequence, at least one secondary structure, and optionally a supplementary nucleotide sequence located at one and/or both ends of the antisense sequence and wherein the secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; a pharmaceutical composition containing such an oligonucleotide as an active ingredient; and a method of treatment using such an oligonucleotide.

Abstract: Nanoparticles containing at least one active ingredient including at least one polymer, preferably a poly(alkylcyanoacrylate), in which the alkyl group, linear or branched, contains from 1 to 12 carbon atoms, and of at least one compound able to complex said active ingredient. The invention also concerns the method for preparing these nanoparticles.

Abstract: A method for identification of a functional biological characteristic of a living material including a) subjecting at least one reference biological material for a functional biological to physical analysis Apr to establish a spectrum SAPr, b) calculating discriminant factors CPnr by a statistical analysis of all or part of the spectrum SAP, c) determining a specific functional descriptor Dfs of the functional biological characteristic from the discriminant factors Cpnr, d) subjecting the living material to be analyzed to steps (a) and (b), and e) comparing the discriminating factors CP of the living material to be analyzed with the specific functional descriptor Dfs to deduce a possible functional biological characteristic of the living material to be analyzed.

Abstract: The present invention relates to a method for analysing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.

Abstract: The present invention relates to a method for analysing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.